SB FIX

Drug Profile

SB FIX

Alternative Names: Factor IX - Sangamo; SB-FIX

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antihaemorrhagics; Gene therapies; Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Blood coagulation factor modulators; DNA binding protein modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haemophilia B

Most Recent Events

  • 11 Jan 2017 Sangamo Therapeutics plans a phase I/II trial for Haemophilia B in 2017
  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 06 Sep 2016 SB FIX receives Orphan Drug status for Haemophilia B in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top